Michael D. West
(CEO)

BioTime, Inc. is a clinical-stage biotechnology company in the field of regenerative medicine headquartered in Alameda, California. BioTime stock is traded on the New York Stock Exchange Market Exchange under ticker symbol BTX. BioTime focuses primarily on two areas: stem cell technology and products for use in regenerative medicine, focusing on areas such as oncology, orthopedics, blood diseases, and blood plasma volume expanders for use in surgery and treatment of traumatic injuries.

BioTime’s products currently on the market include Hextend, a blood plasma volume expander made and distributed by Hospira and research reagents. Hospira was acquired by Pfizer in February 2015.

The company is in clinical trials for age-related macular degeneration (AMD). On November 3, 2014 BioTime's subsidiary Cell Cure Neurosciences announced they had received FDA authorization to initiate a phase I/IIa trial of OpRegen, an embryonic stem cell-derived treatment for the dry-AMD.

BioTime was founded in 1990 in Berkeley, California. The company initially focused on developing processes to cool living bodies, and related projects.

In 2007, the company appointed Michael D. West, Ph.D, as chief executive officer. West had been CSO and CEO of Advanced Cell Technology (and prior to that had founded Geron (NASDAQ: GERN), for which he secured venture capital investment from Kleiner Perkins Caufield & Byers and Venrock.

Also in 2009, BioTime secured $4.72 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to expand its "ACTCellerate" program, which it had acquired the previous year from Advanced Cell Technology for $250,000 plus royalties.

In October 2010, BioTime entered a license agreement with Teva (NYSE: TEVA) to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration, an effort that in 2013 received $1.5 million in funding from Israel's Office of the Chief Scientist.

In 2013, BioTime acquired the stem-cell assets of Geron Corporation, with the aim of restarting its embryonic stem cell-based clinical trial for spinal cord injury.

BioTime has a number of subsidiaries, including:

BioTime’s Board of Directors includes: